Compare GLSI & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLSI | FT |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.9M | 199.8M |
| IPO Year | 2020 | N/A |
| Metric | GLSI | FT |
|---|---|---|
| Price | $16.35 | $7.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 162.6K | 36.1K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $7.79 |
| 52 Week High | $34.10 | $8.35 |
| Indicator | GLSI | FT |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 40.06 |
| Support Level | $12.51 | $7.84 |
| Resistance Level | $29.89 | $8.08 |
| Average True Range (ATR) | 1.12 | 0.06 |
| MACD | 0.64 | -0.00 |
| Stochastic Oscillator | 73.59 | 21.28 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.